New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 17, 2014
08:16 EDTLGND, MRKLigand announces $1M milestone payment triggered by FDA approval of NOXAFIL
Ligand Pharmaceuticals Incorporated (LGND) announces that it has earned a $1M milestone payment as a result of the recent U.S. Food and Drug Administration approval of Merck’s (MRK) NOXAFIL injection. This is a new Captisol-enabled formulation of NOXAFIL for intravenous use. Ligand will sell Captisol to Merck for this product under a commercial supply agreement.
News For LGND;MRK From The Last 14 Days
Check below for free stories on LGND;MRK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 18, 2014
07:57 EDTMRKCambridge Healthtech Institute to hold a summit
6th Annual Bioprocessing Summit to be held in Boston on August 18-22.
August 15, 2014
09:31 EDTLGNDLigand, Avion Pharmaceuticals sign Captisol license agreement
Subscribe for More Information
August 14, 2014
08:12 EDTLGNDLigand signs multi-program Captisol license agreement with Avion Pharmaceuticals
Subscribe for More Information
August 13, 2014
18:02 EDTMRKMerck provides statement on role of PNEUMOVAX 23 in updated ACIP recommendations
Subscribe for More Information
16:52 EDTMRKMerck confirms FDA approval of BELSOMRA
Subscribe for More Information
15:30 EDTMRKFDA approves Belsomra sleep drug
The Food and Drug Administration approved Belsomra tablets for use as needed to treat difficulty in falling and staying asleep. Belsomra is an orexin receptor antagonist and is the first approved drug of this type. Belsomra will be dispensed with an FDA-approved patient Medication Guide that provides instructions for its use and important safety information. Belsomra is a controlled substance because it can be abused or lead to dependence. Belsomra is made by Merck, Sharpe & Dohme.
August 12, 2014
07:44 EDTLGNDMarinus Pharmaceuticals enters into agreement with CyDex Pharmaceuticals
Marinus Pharmaceuticals (MRNS) announced that it has entered into an agreement with CyDex Pharmaceuticals, a wholly owned subsidiary of Ligand Pharmaceutical (LGND), for the clinical use of Captisol, a patent protected, uniquely modified cyclodextrin, whose chemical structure was designed to improve solubility, stability, bioavailability and dosing of active pharmaceutical ingredients. Marinus intends to evaluate optimizing its intravenous dose form of ganaxolone with Captisol.
August 11, 2014
16:11 EDTLGNDLigand announces $200M share repurchase plan
Subscribe for More Information
16:11 EDTLGNDLigand files to sell $225M of convertible senior notes due 2019
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use